Strategies to manage hepatitis C virus (HCV) disease burden

• Autoři: WEDEMEYER H.; DUBERG A. S.; BUTI M.; ROSENBERG W. M.; FRANKOVA S.; ESMAT G.; ÖRMECI N.; VAN VLIERBERGHE H.; GSCHWANTLER M.; AKARCA U.; ALEMAN S.; BALIK I.; BERG T.; BIHL F.; BILODEAU M.; BLASCO A. J.; MELLO C. E. Brandao; BRUGGMANN P.; CALINAS F.; CALLEJA J. L.; CHEINQUER H.; CHRISTENSEN P. B.; CLAUSEN M.; COELHO H. S. M.; CORNBERG M.; CRAMP M. E.; DORE G. J.; DOSS W.; EL-SAYED M. H.; ERGÖR G.; ESTES C.; FALCONER K.; FÉLIX J.; FERRAZ M. L. G.; FERREIRA P. R.; GARCÍA-SAMANIEGO J.; GERSTOFT J.; GIRIA J. A.; GONÇALES F. L. Jr.; PESSÔA M. Guimaraes; HÉZODE C.; HINDMAN S. J.; HOFER H.; HUSA Petr; IDILMAN R.; KABERG M.; KAITA K. D. E.; KAUTZ A.; KAYMAKOGLU S.; KRAJDEN M.; KRARUP H.; LALEMAN W.; LAVANCHY D.; LÁZARO P.; MARINHO R. T.; MAROTTA P.; MAUSS S.; CORREA M. C. Mendes; MORENO C.; MÜLLHAUPT B.; MYERS R. P.; NEMECEK V.; OVREHUS A. L. H.; PARKES J.; PELTEKIAN K. M.; RAMJI A.; RAZAVI H.; REIS N.; ROBERTS S. K.; ROUDOT-THORAVAL F.; RYDER S. D.; SARMENTO-CASTRO R.; SARRAZIN C.; SEMELA D.; SHERMAN M.; SHIHA G. E.; SPERL J.; STÄRKEL P.; STAUBER R. E.; THOMPSON A. J.; URBANEK P.; DAMME P. Van; THIEL I. van; VANDIJCK D.; VOGEL W.; WAKED I.; WEIS N.; WIEGAND J.; YOSRY A.; ZEKRY A.; NEGRO F.; SIEVERT W.; GOWER E.
• Rok publikování: 2014
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: JOURNAL OF VIRAL HEPATITIS
• Fakulta / Pracoviště MU: Lékařská fakulta
• Doi: http://dx.doi.org/10.1111/jvh.12249
• Obor: Epidemiologie, infekční nemoci a klinická imunologie
• Klíčová slova: diagnosis; epidemiology; HCV; mortality; treatment; scenarios; prevalence; incidence; hepatitis C; disease burden
• Popis: The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.